HLB Life Science announced on April 13 that its subsidiary, HLB Life Science R&D, has been selected as a joint research institution for a national research and development project related to the development of medicinal cannabis active pharmaceutical ingredients (APIs).


HLB Life Science R&D Selected as Joint Research Institution for "Development of Medicinal Cannabis APIs" View original image

This consortium is part of the "Development of Technology for Responding to the National Essential Medicines Raw Material Supply Chain Based on Agro-Bio Resources" project, promoted by the Ministry of Agriculture, Food and Rural Affairs and supervised by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry. The project focuses on establishing an advanced production platform for cannabidiol (CBD) APIs and developing cultivation technologies to ensure a stable supply of raw materials, with the ultimate goal of domesticating high-purity CBD APIs that are currently entirely dependent on imports.


The total project budget amounts to approximately 5.7 billion won, of which HLB Life Science R&D will utilize about 1.7 billion won to conduct core research and development, including the identification of non-clinical indications for hemp-derived CBD, establishment of chemical, manufacturing, and quality control (CMC) systems, and preparation for Investigational New Drug (IND) application, among other activities.


HLB Life Science R&D plans to lay the foundation for the domestic production of high-purity CBD APIs, while also strengthening its research and development capabilities and commercialization competitiveness. By accumulating full-cycle R&D experience from non-clinical to CMC and IND stages, the company expects to further expand its pipeline and enhance its technology commercialization potential.



Kim Yeontae, CEO of HLB Life Science R&D, said, "The selection for this project is a significant achievement that once again demonstrates HLB Life Science R&D's research and development capabilities and technological competitiveness. We will work closely with consortium partners to establish a foundation for the domestic production of high-purity CBD APIs and continue to expand related research and development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing